Cancer-associated autoantibodies to MUC1 and MUC4 - A blinded case-control study of colorectal cancer in UK collaborative trial of ovarian cancer screening

International Journal of Cancer

Volumn 134, Issue 9, 2014, Pages 2180-2188

  Pedersen, Johannes W ^a   Gentry Maharaj, Aleksandra ^b   Nøstdal, Alexander ^a   Fourkala, Evangelia Ourania ^b   Dawnay, Anne ^c   Burnell, Matthew ^b   Zaikin, Alexey ^b   Burchell, Joy ^d   Papadimitriou, Joyce Taylor ^d   Clausen, Henrik ^a   Jacobs, Ian ^b   Menon, Usha ^b   Wandall, Hans H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^d GUY S HOSPITAL   (United Kingdom)

Author keywords

autoantibodies; biomarkers; cancer; colon; early diagnosis; glycosylation; microarray; MUC1; MUC4; rectum; seromic profiling

Indexed keywords

AUTOANTIBODY; GLYCOSYLATED PROTEIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MUCIN 1; MUCIN 4; PROTEIN P53;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; BLOOD SAMPLING; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SCREENING; CANCER STAGING; CASE CONTROL STUDY; COLORECTAL CANCER; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; EARLY DIAGNOSIS; FEMALE; HORMONE SUBSTITUTION; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; PROTEIN MICROARRAY; SENSITIVITY AND SPECIFICITY; UNITED KINGDOM;

ADULT; AUTOANTIBODIES; AUTOANTIGENS; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MALE; MIDDLE AGED; MUCIN-1; MUCIN-4; OVARIAN NEOPLASMS; PROTEIN ARRAY ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84896736154     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28538     Document Type: Article

References (50)

1. Lu H, Goodell V, Disis ML,. Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. J Proteome Res 2008; 7: 1388-94.
2. Tainsky MA,. Genomic and proteomic biomarkers for cancer: a multitude of opportunities. Biochim Biophys Acta 2009; 1796: 176-93.
3. Mintz PJ, Kim J, Do KA, et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 2003; 21: 57-63.
4. Lubin R, Schlichtholz B, Bengoufa D, et al. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 1993; 53: 5872-6.
5. Kawabata R, Wada H, Isobe M, et al. Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients. Int J Cancer 2007; 120: 2178-84.
6. Liu WL, Zhang G, Wang JY, et al. Proteomics-based identification of autoantibody against CDC25B as a novel serum marker in esophageal squamous cell carcinoma. Biochem Biophys Res Commun 2008; 375: 440-5.
7. Snijdewint FG, von Mensdorff-Pouilly S, Karuntu-Wanamarta AH, et al. Cellular and humoral immune responses to MUC1 mucin and tandem-repeat peptides in ovarian cancer patients and controls. Cancer Immunol Immunother 1999; 48: 47-55.
8. Chapman C, Murray A, Chakrabarti J, et al. Autoantibodies in breast cancer: their use as an aid to early diagnosis. Ann Oncol 2007; 18: 868-73.
9. Hellstrom I, Friedman E, Verch T, et al. Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients. Cancer Epidemiol Biomarkers Prev 2008; 17: 1520-6.
10. Bode AM, Dong Z,. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004; 4: 793-805.
11. Hakomori S,. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci USA 2002; 99: 10231-3.
12. Saldova R, Wormald MR, Dwek RA, et al. Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis. Dis Markers 2008; 25: 219-32.
13. Springer GF,. T and Tn, general carcinoma autoantigens. Science 1984; 224: 1198-206.
14. Tarp MA, Clausen H,. Mucin-type O-glycosylation and its potential use in drug and vaccine development. Biochim Biophys Acta 2008; 1780: 546-63.
15. Hollingsworth MA, Swanson BJ,. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004; 4: 45-60.
16. Hattrup CL, Gendler SJ,. Structure and function of the cell surface (tethered) mucins. Annu Rev Physiol 2008; 70: 431-57.
17. Taylor-Papadimitriou J, Burchell J, Miles DW, et al. MUC1 and cancer. Biochim Biophys Acta 1999; 1455: 301-13.
18. Pedersen JW, Blixt O, Bennett EP, et al. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int J Cancer 2011; 128: 1860-71.
19. Wandall HH, Blixt O, Tarp MA, et al. Cancer biomarkers defined by autoantibody signatures to aberrant O-glycopeptide epitopes. Cancer Res 2010; 70: 1306-13.
20. Blixt O, Clo E, Nudelman AS, et al. A high-throughput O-glycopeptide discovery platform for seromic profiling. J Proteome Res 2010; 9: 5250-61.
21. Pepe MS, Feng Z, Janes H, et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst 2008; 100: 1432-8.
22. Pedersen JW, Gentry-Maharaj A, Fourkala EO, et al. Early detection of cancer in the general population: a blinded case-control study of p53 autoantibodies in colorectal cancer. Br J Cancer 2013; 108: 107-14.
23. Menon U, Gentry-Maharaj A, Ryan A, et al. Recruitment to multicentre trials-lessons from UKCTOCS: descriptive study. BMJ 2008; 337: a2079.
24. Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol 2009; 10: 327-40.
25. Cramer DW, Bast RC, Jr, Berg CD, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) 2011; 4: 365-74.
26. Chechlinska M, Kowalewska M, Nowak R,. Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat Rev Cancer 2010; 10: 2-3.
27. Furr AE, Ranganathan S, Finn OJ,. Aberrant expression of MUC1 mucin in pediatric inflammatory bowel disease. Pediatr Dev Pathol 2010; 13: 24-31.
28. Itzkowitz SH, Bloom EJ, Lau TS, et al. Mucin associated Tn and sialosyl-Tn antigen expression in colorectal polyps. Gut 1992; 33: 518-23.
29. Itzkowitz SH, Young E, Dubois D, et al. Sialosyl-Tn antigen is prevalent and precedes dysplasia in ulcerative colitis: a retrospective case-control study. Gastroenterology 1996; 110: 694-704.
30. Diamandis EP,. Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 2010; 102: 1462-7.
31. Pitteri SJ, Hanash SM,. Confounding effects of hormone replacement therapy in protein biomarker studies. Cancer Epidemiol Biomarkers Prev 2011; 20: 134-9.
32. Chapman CJ, Thorpe AJ, Murray A, et al. Immunobiomarkers in small cell lung cancer: potential early cancer signals. Clin Cancer Res 2011; 17: 1474-80.
33. Boyle P, Chapman CJ, Holdenrieder S, et al. Clinical validation of an autoantibody test for lung cancer. Ann Oncol 2011; 22: 383-9.
34. Gnjatic S, Ritter E, Buchler MW, et al. Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci USA 2010; 107: 5088-93.
35. Qiu J, Choi G, Li L, et al. Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol 2008; 26: 5060-6.
36. Wilschut JA, Habbema JD, van Leerdam ME, et al. Fecal occult blood testing when colonoscopy capacity is limited. J Natl Cancer Inst 2011; 103: 1741-51.
37. Church TR, Wandell M, Lofton-Day C, et al. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Gut 2013. doi:10.1136/gutjnl-2012-304149.
38. deVos T, Tetzner R, Model F, et al. Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clin Chem 2009; 55: 1337-46.
39. Tanzer M, Balluff B, Distler J, et al. Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS One 2010; 5: e9061.
40. Lang C, Unteregger G, Kartarius S, et al. p53 autoantibodies in patients with urological tumours. Br J Urol 1998; 82: 721-6.
41. Bergqvist AS, Bergqvist M, Brattstrom D, et al. Serum p53 autoantibodies as prognostic marker in patients with oesophageal carcinoma. Anticancer Res 2001; 21: 4141-5.
42. Tang R, Ko MC, Wang JY, et al. Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients. Int J Cancer 2001; 94: 859-63.
43. Hogdall EV, Hogdall CK, Blaakaer J, et al. P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis. APMIS 2002; 110: 545-53.
44. Goodell V, Salazar LG, Urban N, et al. Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer. J Clin Oncol 2006; 24: 762-8.
45. Anderson KS, Wong J, Vitonis A, et al. p53 autoantibodies as potential detection and prognostic biomarkers in serous ovarian cancer. Cancer Epidemiol Biomarkers Prev 2010; 19: 859-68.
46. Budiu RA, Mantia-Smaldone G, Elishaev E, et al. Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunol Immunother 2011; 60: 975-84.
47. von Mensdorff-Pouilly S, Verstraeten AA, Kenemans P, et al. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. J Clin Oncol 2000; 18: 574-83.
48. Kurtenkov O, Klaamas K, Mensdorff-Pouilly S, et al. Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival. Acta Oncol 2007; 46: 316-23.
49. Hamanaka Y, Suehiro Y, Fukui M, et al. Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer 2003; 103: 97-100.
50. Hirasawa Y, Kohno N, Yokoyama A, et al. Natural autoantibody to MUC1 is a prognostic indicator for non-small cell lung cancer. Am J Respir Crit Care Med 2000; 161: 589-94.